In 2018 the European Haemophilia Consortium (EHC) received funding from the below income sources. The accounts of the EHC are audited by an external auditor and approved by its members during its Annual General Assembly.

 


EHC Funding 2018 - Industry versus non-industry funding

Source of incomeAmount in €% of the total income
Non-industry606,61532%
Industry1,296,88668%
Highest industry contribution243,00013%

EHC non-industry funding - 2018

Funding source Amount in €% of the total income
EHC membership and other fees28,3251%
EHC Conference income and conference-related fees65,8903%
Volunteer (non-remunerated) contributions512,40027%
Subtotal606,61532%

EHC industry-related funding - 2018

Funding sourceAmount in €% of total income
Alnylam212,50011%
Bayer45,0002%
Biotest20,0001%
BioMarin75,0004%
CSL Behring65,0003%
Kedrion37,0002%
Novo Nordisk45,0002%
Pfizer192,50010%
Roche132,5007%
Sanofi-Genzyme7,5000%
Shire170,0009%
Sobi243,00013%
Spark40,0002%
UniQure11,8861%
Subtotal1,296,88668%